Alzheimer's Tau Vaccine (AADvac1)
Jump to navigation
Jump to search
Indications
- experimental vaccine for Alzheimer's disease
Dosage
- 40 ug SQ monthly for 6 doses
- subsequently quarterly booster injections for 5 doses
- 11 total doses, each 40 ug SQ
Adverse effects
- confusion, mostly transient in 6 AADvac1-treated patients
- injection site reactions
Mechanism of action
- slows accumulation of plasma neurofilament light (NfL)
Clinical trials
ADAMANT trial: phase II placebo-controlled trial
- safe & elicits immune responses in people with mild Alzheimer's disease
- no effects on cognitive decline in overall population of trial participants[1][2]
- subgroups showed slower cognitive decline[1][2]
References
- ↑ 1.0 1.1 1.2 George J Alzheimer's Tau Vaccine Shows Immune Response, Safety. Exploratory, post hoc analyses hint at plasma NfL changes, and in some, slower cognitive decline. MedPage Today June 14, 2021 https://www.medpagetoday.com/neurology/alzheimersdisease/93098
- ↑ 2.0 2.1 2.2 Novak P, Kovacech, B, Katina S et al ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer' s disease. Nat Aging 2021. 1, 521-534. April 28 Not indexed in PubMed https://www.nature.com/articles/s43587-021-00070-2
- ↑ Novak P, Zilka N, Zilkova M et al AADvac1, an Active Immunotherapy for Alzheimer's Disease and Non Alzheimer Tauopathies: An Overview of Preclinical and Clinical Development. J Prev Alzheimers Dis. 2019;6(1):63-69. PMID: https://www.ncbi.nlm.nih.gov/pubmed/30569088 Review.
- ↑ Novak P, Schmidt R, Kontsekova E et al FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer's disease. Alzheimers Res Ther. 2018 Oct 24;10(1):108. . PMID: https://www.ncbi.nlm.nih.gov/pubmed/30355322 Free PMC article. Clinical Trial.
- ↑ Novak P, Schmidt R, Kontsekova E et al Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Neurol. 2017 Feb;16(2):123-134. Epub 2016 Dec 10. PMID: https://www.ncbi.nlm.nih.gov/pubmed/27955995 Clinical Trial
- ↑ Kontsekova E, Zilka N, Kovacech B et al First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model. Alzheimers Res Ther. 2014 Aug 1;6(4):44. PMID: https://www.ncbi.nlm.nih.gov/pubmed/25478017 Free PMC article.